Living with heart failure

Heart failure (HF) remains a global health concern affecting approximately 64.3 million people worldwide. In sub-Saharan Africa the pattern of HF is diverse and different to what is reported by the Global North, such as the relatively young age of participants reported in The Sub-Saharan African Survey of HF (THESUS-HF) study. Despite notable progress over the past 2 decades in advancing the understanding of HF in Africa, important knowledge gaps persist. These include outdated data on access to care and a lack of information regarding the incidence, aetiology, availability, and affordability of HF medications. The THESUS-HF II study, under the umbrella of the Pan African Cardiac Society is currently underway. So far 16 countries participate, and more than 1 400 patients have been recruited (Figure 1). It is expected that the study will provide more understanding into access to care as well as comorbidities, risk factors and outcomes of HF.

Authors

Institutions

Publication Details

Journal
SA Heart
Published
2025-01-01
DOI
https://doi.org/10.24170/22-2-7587
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Living with heart failure

Karen S Sliwa, S. Allie
SA Heart
Heart Failure Treatment and Management
article

Living with heart failure

Karen S Sliwa, S. Allie
article en

Abstract

Heart failure (HF) remains a global health concern affecting approximately 64.3 million people worldwide. In sub-Saharan Africa the pattern of HF is diverse and different to what is reported by the Global North, such as the relatively young age of participants reported in The Sub-Saharan African Survey of HF (THESUS-HF) study. Despite notable progress over the past 2 decades in advancing the understanding of HF in Africa, important knowledge gaps persist. These include outdated data on access to care and a lack of information regarding the incidence, aetiology, availability, and affordability of HF medications. The THESUS-HF II study, under the umbrella of the Pan African Cardiac Society is currently underway. So far 16 countries participate, and more than 1 400 patients have been recruited (Figure 1). It is expected that the study will provide more understanding into access to care as well as comorbidities, risk factors and outcomes of HF.

SA HeartVol. 22(2)
University of Cape Town (ZA), Groote Schuur Hospital (ZA)
Openalex Percentile: Top 74%
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.